The role of immunotherapy in the treatment of patients with advanced squamous cell carcinoma of the head and neck (SCCHN) is explored through two cases.
The cases presented are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice.
This activity is intended for hematologist/oncologists, surgeons, and other healthcare professionals who treat patients with SCCHN.
The goal of this activity is to increase understanding of current approaches to treating advanced SCCHN with immunotherapy.
Learning Objectives:
- Have increased knowledge regarding the clinical study designs, as well as efficacy and safety findings, from trials that have evaluated immune checkpoint inhibitor regimens in patients with recurrent or metastatic SCCHN.
- Have greater competence related to identifying tumor characteristics and other clinical features that guide treatment selection in patients with recurrent or metastatic SCCHN.
- Have greater competence related to strategies for monitoring and managing treatment-related adverse events.
Approximate Time to Complete: 60 minutes
Credit Available: May 15, 2020 - May 15, 2021
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)